CONMED Corporation (Nasdaq:CNMD) today announced
financial results for the first quarter ended March 31, 2016.
First Quarter 2016 Highlights
- Sales were $181.2 million, an increase
of 1.8% compared to the first quarter of 2015. On a constant
currency basis, sales increased 5.0% over the prior-year
period.
- GAAP gross margin expanded 200 basis
points year over year to 53.9%.
- Adjusted gross margin expanded 120
basis points year over year to 54.4%.
- Diluted net loss per share (GAAP) was
$0.08, compared to diluted net earnings per share (GAAP) of $0.23
in the first quarter of 2015.
- Adjusted diluted net earnings per
share(1) were $0.42 versus $0.49 in the prior-year period.
- Revising 2016 guidance for reported
sales and adjusted diluted net earnings per share higher due to
updated foreign exchange impact.
- Completed the acquisition of
SurgiQuest, Inc. on January 4, 2016.
- Added Martha Goldberg Aronson to its
Board of Directors.
“We accomplished several important milestones in the quarter,
and we are pleased with our sales growth in General Surgery.
Further, the contribution from the AirSeal® System was in line with
our expectations,” commented Curt R. Hartman, CONMED’s President
and Chief Executive Officer. “Despite a slow start to the year for
capital sales in the international markets, we saw growth in all
three of our main product categories domestically, with U.S.
Orthopedics posting its third consecutive quarter of positive
growth. We remain confident in our financial outlook for the year
as investments in our strategic initiatives and in product
development translate into further operating improvements.”
Sales Analysis
For the quarter ended March 31, 2016, domestic sales, which
represented 53.0% of total revenue, increased 10.4% as a result of
growth across all three of the Company’s product categories, led by
General Surgery. The SurgiQuest acquisition contributed to 19.4%
year-over-year growth in the U.S. General Surgery business.
International sales, which represented 47.0% of total revenue,
declined 6.4% compared to the first quarter of 2015 on a reported
basis. Foreign currency exchange rates, including the effects of
the FX hedging program, had a negative impact of $5.7 million on
first quarter sales. In constant currency, international sales
decreased 0.3% versus the prior-year period.
Earnings Analysis
For the quarter ended March 31, 2016, reported net loss totaled
$2.3 million, compared to reported net earnings of $6.3 million a
year ago. Reported diluted net loss per share was $0.08 in the
quarter, compared to reported diluted net earnings per share of
$0.23 in the prior-year period. Reported net loss for 2016 includes
business acquisition, restructuring, and debt refinancing costs,
and reported net earnings for 2015 include restructuring costs. The
effect of each of these items on reported net earnings/loss and
reported diluted net earnings/loss per share appears in the
reconciliation of GAAP to non-GAAP measures below.
As previously announced, beginning in 2016, the Company is
excluding after-tax costs of special items including acquisitions,
restructuring, and debt refinancing, as well as amortization of
intangible assets, net of tax, from its adjusted diluted net
earnings per share. Excluding the impact of these items, adjusted
net earnings(2) of $11.6 million decreased 15.3% year over year and
adjusted diluted net earnings per share (1) of $0.42 decreased
14.3% year over year. The decline in adjusted net earnings was
largely attributable to the impact of unfavorable foreign exchange
rates, partially offset by a lower tax rate and improved gross
margin during the quarter.
2016 Outlook
The Company is revising its 2016 guidance for reported sales and
adjusted diluted net earnings per share higher due to the updated
foreign exchange impact anticipated for the year. The Company now
forecasts reported 2016 sales in the range of $768 to $778 million,
compared to the previous range of $760 to $770 million. This
revenue forecast includes constant currency organic sales growth of
1% to 3%, sales related to the SurgiQuest acquisition of $55 to $60
million, and an updated negative impact of foreign exchange of $13
to $15 million (based on foreign currency exchange rates as of
April 22, 2016).
Based on its revised 2016 reported sales estimate range of $768
to $778 million, the Company now forecasts 2016 adjusted diluted
net earnings per share in the range of $1.95 to $2.05, compared to
the previous range of $1.85 to $1.95, which reflects the favorable
movement in foreign exchange rates. The adjusted diluted net
earnings per share estimates for 2016 exclude the cost of special
items including acquisition costs, restructuring costs, and debt
refinancing, which are estimated in the range of $18 to $20
million, net of tax, and amortization of intangible assets, which
are now estimated in the range of $12 to $14 million, net of tax,
compared to the previous range of $14 to $16 million, net of tax,
based on the close of the SurgiQuest transaction.
Supplemental Financial Disclosures
(1) A reconciliation of reported diluted net earnings per share
to adjusted diluted net earnings per share, a non-GAAP financial
measure appears below.
(2) A reconciliation of reported net earnings to adjusted net
earnings, a non-GAAP financial measure appears below.
In conjunction with this earnings press release, CONMED has
prepared supplemental financial disclosures which are available on
the home page of the “Investors – Financial Reports” section of the
Company’s web site at www.conmed.com.
Conference Call
The Company’s management will host a conference call today at
4:30 p.m. ET to discuss its first quarter 2016 results.
To participate in the conference call, dial 877-573-5235
(domestic) or 503-406-4448 (international) and enter the passcode
83879064.
This conference call will also be webcast and can be accessed
from the “Investors” section of CONMED's website at www.conmed.com.
The webcast replay of the call will be available at the same site
approximately one hour after the end of the call.
A recording of the call will also be available from 7:30 p.m. ET
on Wednesday, April 27, 2016 until 11:59 p.m. ET on Wednesday, May
4, 2016. To hear this recording, dial 855-859-2056 (domestic) or
404-537-3406 (international) and enter the passcode 83879064.
About CONMED Corporation
CONMED is a medical technology company that provides surgical
devices and equipment for minimally invasive procedures. The
Company’s products are used by surgeons and physicians in a variety
of specialties, including orthopedics, general surgery, gynecology,
neurosurgery and gastroenterology. The Company distributes its
products worldwide from several manufacturing locations. CONMED has
a direct selling presence in 17 countries and international sales
constitute approximately 50% of the Company’s total sales.
Headquartered in Utica, New York, the Company employs approximately
3,400 people. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release and today’s conference call may contain
forward-looking statements based on certain assumptions and
contingencies that involve risks and uncertainties, which could
cause actual results, performance, or trends to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. For example, in addition to general industry
and economic conditions, factors that could cause actual results to
differ materially from those in the forward-looking statements may
include, but are not limited to, the risks factors discussed in the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2015. Any and all forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and relate to the Company’s
performance on a going-forward basis. The Company believes that all
forward-looking statements made by it have a reasonable basis, but
there can be no assurance that management’s expectations, beliefs
or projections as expressed in the forward-looking statements will
actually occur or prove to be correct.
Supplemental Information - Reconciliation of GAAP to Non-GAAP
Financial Measures
The Company supplements the reporting of its financial
information determined under accounting principles generally
accepted in the United States (GAAP) with certain non-GAAP
financial measures, including percentage sales growth in constant
currency; adjusted gross profit; cost of sales excluding specified
items; adjusted selling and administrative expenses; adjusted
operating income; adjusted effective income tax rate; adjusted net
earnings and adjusted diluted net earnings per share (EPS). The
Company believes that these non-GAAP measures provide meaningful
information to assist investors and shareholders in understanding
our financial results and assessing our prospects for future
performance. Management believes percentage sales growth in
constant currency and the other adjusted measures described above
are important indicators of our operations because they exclude
items that may not be indicative of, or are unrelated to, our core
operating results and provide a baseline for analyzing trends in
the Company’s underlying businesses. Further, the presentation of
EBITDA is a non-GAAP measurement that management considers useful
for measuring aspects of the Company’s cash flow. Management uses
these non-GAAP financial measures for reviewing the operating
results and analyzing potential future business trends in
connection with our budget process and bases certain management
incentive compensation on these non-GAAP financial measures.
To measure percentage sales growth in constant currency, the
Company removes the impact of changes in foreign currency exchange
rates that affect the comparability and trend of sales. To measure
earnings performance on a consistent and comparable basis, the
Company excludes certain items that affect the comparability of
operating results and the trend of earnings. These adjustments are
irregular in timing, may not be indicative of our past and future
performance and are therefore excluded to allow investors to better
understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may
not be possible to compare these financial measures with other
companies' non-GAAP financial measures having the same or similar
names. These adjusted financial measures should not be considered
in isolation or as a substitute for reported sales growth, gross
profit, cost of sales, selling and administrative expenses,
operating income, effective income tax rate, net earnings and
diluted net earnings per share, the most directly comparable GAAP
financial measures. These non-GAAP financial measures are an
additional way of viewing aspects of our operations that, when
viewed with our GAAP results and the reconciliations to
corresponding GAAP financial measures below, provide a more
complete understanding of our business. The Company strongly
encourages investors and shareholders to review our financial
statements and publicly-filed reports in their entirety and not to
rely on any single financial measure.
Consolidated Condensed Statements of
Income (Loss)
(in thousands, except per share amounts,
unaudited)
Three Months Ended March 31, 2016
2015 Net sales $
181,201 $ 177,940 Cost of sales 83,461
85,658 Gross profit 97,740
92,282 % of sales 53.9 % 51.9 % Selling and
administrative expense 85,943 74,786 Research & development
8,258 6,542 Income from
operations 3,539 10,954 %
of sales 2.0 % 6.2 % Other expense 2,942 - Interest expense
3,830 1,460 Income (loss) before
income taxes (3,233 ) 9,494 Provision (benefit) for income taxes
(968 ) 3,182 Net income (loss) $
(2,265 ) $ 6,312 Basic EPS $ (0.08 ) $
0.23 Diluted EPS $ (0.08 ) $ 0.23 Basic shares 27,721 27,573
Diluted shares 27,721 27,820
Consolidated Condensed Balance
Sheets
(in thousands, unaudited)
March 31, December 31, 2016
2015 Assets: Cash and cash equivalents $
19,894 $ 72,504 Accounts receivable, net 134,412 133,863
Inventories 185,108 166,894 Other current assets 28,520
20,076
Total Current Assets 367,934
393,337 Property, plant and equipment, net 126,827 125,452 Goodwill
398,387 260,651 Other intangible assets, net 434,196 308,171 Other
assets 15,439 14,089
Total
Assets $ 1,342,783 $ 1,101,700
Liabilities and Shareholders' Equity: Current liabilities $
103,158 $ 119,718 Long-term debt, excluding current maturities
511,598 269,471 Other liabilities 145,738 127,438 Shareholders'
equity 582,289 585,073
Total
Liabilities and Shareholders' Equity $ 1,342,783
$ 1,101,700
Consolidated Condensed Statements of
Cash Flows
Three Months Ended March 31, 2016 and
March 31, 2015
(in thousands, unaudited)
2016 2015
Operating Activities Net income (loss) $ (2,265 ) $ 6,312
Depreciation and amortization 13,258 10,170 Changes in operating
assets and liabilities and other, net (28,273 )
(1,673 )
Net cash provided by (used in) operating activities
(17,280 ) 14,809
Investing
Activities Payments related to business acquisitions, net of
cash acquired (256,424 ) (853 ) Purchases of property, plant and
equipment (2,789 ) (4,061 )
Net cash used in
investing activities (259,213 ) (4,914 )
Financing Activities Payments on debt (2,188 ) - Proceeds of
debt 253,005 17,000 Payments related to debt issue costs (5,556 ) -
Payment related to distribution agreement (16,667 ) (16,667 )
Dividend payments on common stock (5,542 ) (5,510 ) Other, net
110 543
Net cash provided by (used
in) financing activities 223,162 (4,634 ) Effect of
exchange rate change on cash and cash equivalents 721
(5,864 ) Net decrease in cash and cash equivalents (52,610 )
(603 ) Cash and cash equivalents at beginning of period
72,504 66,332
Cash and cash equivalents at
end of period $ 19,894 $ 65,729
Sales Summary
(in millions, unaudited)
Three Months Ended March 31,
% Change
Domestic
International 2016
2015
AsReported
ConstantCurrency
AsReported
AsReported
ConstantCurrency
Orthopedic Surgery $ 93.4 $ 98.6 -5.2 %
-1.2 % 0.9 % -9.0 % -2.5 % General
Surgery 75.9 66.1 14.9 % 16.7 % 19.4 % 6.1 % 11.2 % Surgical
Visualization 11.9 13.2
-10.7 % -7.7 % 4.0 % -22.9 %
-17.5 % $ 181.2 $ 177.9 1.8 %
5.0 % 10.4 % -6.4 % -0.3
% Single-use products $ 144.9 $ 140.1 3.4 % 6.7 % 8.3 % -1.8
% 4.9 % Capital products 36.3 37.8
-4.0 % -1.1 % 21.3 %
-19.4 % -15.1 % $ 181.2 $ 177.9
1.8 % 5.0 % 10.4 % -6.4 %
-0.3 %
Domestic
$
96.1
$
87.0
10.4
%
10.4
%
International
85.1
90.9
-6.4
%
-0.3
%
$
181.2
$
177.9
1.8
%
5.0
%
Reconciliation of Reported Net Earnings
to Adjusted Net Earnings
(in thousands, except per share amounts,
unaudited)
Three Months Ended March 31, 2016
GrossProfit
Selling
&AdministrativeExpense
OperatingIncome
OtherExpense
TaxExpense
EffectiveTax Rate
NetIncome(Loss)
DilutedEPS
As reported $ 97,740 $ 85,943
$ 3,539 $ 2,942
$ (968 ) 29.9 % $ (2,265 )
$ (0.08 ) % of sales 53.9 % 47.4 %
2.0 %
Restructuring costs (1) 864 (2,791 )
3,655 - 1,156 2,499 0.09 Business acquisition (2) - (9,045 ) 9,045
- 2,872 6,173 0.22 Debt refinancing costs (3) -
- -
(2,942 ) 930
2,012
0.07 $ 98,604 $ 74,107
$ 16,239 $ -
$ 3,990 32.2 % $ 8,419 $ 0.30 % of
sales 54.4 % 40.9 % 9.0 %
Amortization of
intangible assets
$ 1,500 $ (3,496 ) $ 4,996 $ - $ 1,799 3,197
0.12
Adjusted earnings $ 11,616
$ 0.42
Three Months
Ended March 31, 2015
GrossProfit
Selling
&AdministrativeExpense
OperatingIncome
OtherExpense
TaxExpense
EffectiveTax Rate
NetIncome
DilutedEPS
As reported $ 92,282 $ 74,786
$ 10,954 $ -
$ 3,182 33.5 % $ 6,312
$ 0.23 % of sales 51.9 % 42.0 % 6.2 %
Restructuring costs(1) 2,329
(6,180 ) 8,509 -
3,064
5,445 0.19
$ 94,611 $ 68,606 $
19,463 $ - $ 6,246
34.7 % $ 11,757 $ 0.42 % of sales 53.2 % 38.6 % 10.9
%
Amortization of
intangible assets
$ 1,500 $ (1,549 ) $ 3,049 $ - $ 1,098 1,951
0.07
Adjusted earnings $ 13,708
$ 0.49
(1) In 2016 and 2015, the Company
restructured certain sales, marketing, and administrative functions
andincurred severance and other related costs. Additionally, in
2015, the Company continued and substantiallycompleted the
operational restructuring, including the consolidation of its
Centennial, Coloradomanufacturing operations into other existing
CONMED manufacturing facilities.
(2) In 2016, the Company incurred
investment banking fees, consulting fees, legal fees and
integration relatedcosts associated with the acquisition of
SurgiQuest, Inc.
(3) In 2016, in conjunction with the
acquisition of SurgiQuest, Inc., the Company refinanced its
existing creditfacility and incurred one-time fees associated with
an agreement between the Company and JP MorganChase Bank, N.A., as
well as costs associated with the early extinguishment of debt.
Reconciliation of Reported Net Income
to EBITDA & Adjusted EBITDA
(in thousands, unaudited)
Three Months Ended March 31, 2016
2015 Net income
(loss) $ (2,265 ) $ 6,312 Provision (benefit)
for income taxes (968 ) 3,182 Interest expense 3,830 1,460
Depreciation 4,986 4,633 Amortization 8,012
5,390 EBITDA $ 13,595 $
20,977 Stock based compensation 1,769 1,256
Restructuring costs 3,655 8,509 Business acquisition 9,045 - Debt
refinancing costs 2,942 -
Adjusted EBITDA $ 31,006 $ 30,742
EBITDA Margin EBITDA 7.5 % 11.8 % Adjusted
EBITDA 17.1 % 17.3 %
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160427006544/en/
CONMED CorporationLuke A. Pomilio,
315-624-3202Chief Financial
OfficerLukePomilio@conmed.com
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CONMED (NASDAQ:CNMD)
Historical Stock Chart
From Apr 2023 to Apr 2024